Novavax, Inc. (BMV:NVAX)

Market Cap	25.32B
Revenue (ttm)	20.34B
Net Income (ttm)	7.97B
Shares Out	n/a
EPS (ttm)	47.99
PE Ratio	3.18
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	483
Open	155.16
Previous Close	155.16
Day's Range	155.16 - 155.16
52-Week Range	106.50 - 231.28
Beta	n/a
RSI	46.84
Earnings Date	Nov 6, 2025

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NVAX

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD